Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZMRYF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
HMBD-501
|
|||||
| Synonyms |
HMBD-501; ENV-501
Click to Show/Hide
|
|||||
| Organization |
Hummingbird Bioscience (Originator);Endeavor BioMedicines
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-HER3 mAb
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-3 (ERBB3); Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Gastric cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Melanoma |
1 Trials
|
||||||||
| Pancreatic cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|